Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC.
Commentary|Articles|March 31, 2025
The Long-Term Impact of COVID-19 on Oncology Care: A Five-Year Retrospective
Author(s)Courtney Flaherty
Fact checked by: Caroline Seymour
Experts across specialties reflect on the long-term effects of COVID-19 on several aspects of cancer care.
Advertisement
Advertisement
Five years after the onset of the COVID-19 pandemic, the oncology field continues to grapple with its repercussions. From fundamental shifts in patient management, including the introduction of telemedicine, to trial disruptions and workforce challenges, the pandemic has reshaped every aspect of oncology care. Although some of these adaptations offer unique benefits, others require strategic solutions, and the oncology community must continue to adapt and innovate to ensure optimal patient outcomes.
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.
The c-Met–directed ADC-based combination was designated for mCRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy.
Pooled data from 3 randomized trials showed ropeginterferon alfa-2b improved responses vs phlebotomy alone but not vs hydroxyurea in polycythemia vera.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Advertisement
Advertisement